Tamara A. Sussman

Poly(ADP-Ribose) Polymerase Inhibition in Melanoma: Biological Rationale, Emerging Clinical Evidence, and Biomarker Selection

Immune checkpoint inhibitors and other targeted therapies have substantially improved outcomes for patients with advanced melanoma; however, effective treatment options remain limited following treatment resistance. Poly(ADP-ribose) polymerase (PARP) inhibitors are an established...

Tumor-informed molecular residual disease in resected mucosal and cutaneous squamous cell carcinomas of the head and neck

Abstract Patients with resected mucosal (HNSCC) or cutaneous (cSCC) squamous carcinomas of the head and neck undergo adjuvant therapy based on clinicopathologic prognosticators. Most patients are overtreated or undertreated, with substantial morbidity from locoregional recurrence...